Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Hospira Bids To Acquire Javelin | Contract Pharma

What are you searching for?

Sign in
Breaking News

Hospira Bids To Acquire Javelin

Javelin Pharmaceuticals, a specialty pharma in the pain management sphere, has received an acquisition bid from Discus, a subsidiary of Hospira, leading Javelin to cancel its previous merger agreement with Myriad Pharmaceuticals.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Javelin Pharmaceuticals, a specialty pharma in the pain management sphere, has received an acquisition bid from Discus, a subsidiary of Hospira, leading Javelin to cancel its previous merger agreement with Myriad Pharmaceuticals. The move triggers a $4.4 million termination fee, which Hospira will pay.

Hospira will pay $2.20 per share of Javelin, a 60% premium from Javelin’s previous share price, for a total of $141 million for all outstanding shares. Javelin will also be able to borrow as much as $4.5 million from Hospira to fund operations until the end of the merger, and $8.3 million to repay a similar loan that was taken out when the Myriad merger was signed.

According to a statement from Javlin’s chief executive officer, Martin Driscoll, Javelin is required to negotiate in good faith with Myriad for a period of five business days. If MPI does not “favorably adjust the terms of its offer,” then Javelin will follow through with the Hospira bid.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters